Philadelphia
Biomeme is the developer of a platform that transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance.
Estimated valuation today
$42M
-6.87% since last round
Calculated based on estimated multiplier and revenue.
Revenue
Update this based on your knowledge or projections. Calculations use last 12 months revenue.
Hype Multiple
Currently selected comps have a median growth rate of 11.40%
This premium represents how much of a bonus the company receives on its valuation for its additional growth compared to the selected public comps. The valuation is multipled by the Hype Multiple to get the final valuation. You can read more about this from a16z.
multiple
In an event of a merger or aquisition, the investors will get their money back first. In this case, the investors got paid out and there was sufficent money left for employees. Everything above this point means you can exercise your options for a profit.
The last round was 5 years ago.
Date
April 2017
Valuation
$45M
Amount raised
$13M
We estimate company valuation by comparing it to similiar companies in the public market. The revenue multipler is calculated by taking a company's current valuation and dividing it by its total revenue.
Multiple at last round
1.64x revenue
Today's multiple
1.64x revenue
Change
0.00%
Companies
Industry – Healthcare
Last updated 5 mins ago.
| Remove | Name | Ticker | Price multiple |
|---|---|---|---|
| Biomeme | 1.64x | ||
| 1Life Healthcare Inc | ONEM | 4.38x | |
| HCA Holdings Inc | HCA | 1.04x | |
| Tenet Healthcare Corporation | THC | 0.37x | |
| Quest Diagnostics Incorporated | DGX | 1.51x | |
| Humana Inc | HUM | 0.67x |
| Date | Round | Amount raised | Price per share (Preferred) | Valuation |
|---|---|---|---|---|
| Apr 2017 | Series Seed | $12.87MM | $1.46 | $45MM |
With a revenue of $17M and a Hype Multiple of 1.5x,
Biomeme is estimated to be worth $42M.